Induction of cellular immune responses in patients with stage-I multiple myeloma after vaccination with autologous idiotype-pulsed dendritic cells.
Dez 2010 - J. Immunother.; 34(1):1537-4513 [PMID:21150718]
[Röllig C] [Schmidt C] [Bornhäuser M] [Ehninger G] [Schmitz M] [Auffermann-Gretzinger S]

Dendritic cell-based immunotherapy for prostate cancer.
Nov 2010 - Clin. Dev. Immunol.; 2010:1740-2530 [PMID:21076523]
[Jähnisch H] [Füssel S] [Kiessling A] [Wehner R] [Zastrow S] [Bachmann M] [Rieber EP] [Wirth MP] [Schmitz M]

Advances in specific immunotherapy for prostate cancer.
Feb 2008 - Eur. Urol.; 53(4):0302-2838 [PMID:18061335]
[Kiessling A] [Füssel S] [Wehner R] [Bachmann M] [Wirth MP] [Rieber EP] [Schmitz M]

Vaccination of hormone-refractory prostate cancer patients with peptide cocktail-loaded dendritic cells: results of a phase I clinical trial.
Apr 2006 - Prostate; 66(8):0270-4137 [PMID:16482569]
[Fuessel S] [Meye A] [Schmitz M] [Zastrow S] [Linné C] [Richter K] [Löbel B] [Hakenberg OW] [Hoelig K] [Rieber EP] [Wirth MP]

Induction of cellular immune responses against carcinoembryonic antigen in patients with metastatic tumors after vaccination with altered peptide ligand-loaded dendritic cells.
Dez 2005 - Cancer Immunol. Immunother.; 55(3):0340-7004 [PMID:16034561]
[Babatz J] [Röllig C] [Löbel B] [Folprecht G] [Haack M] [Günther H] [Köhne CH] [Ehninger G] [Schmitz M] [Bornhäuser M]

Large-scale immunomagnetic selection of CD14+ monocytes to generate dendritic cells for cancer immunotherapy: a phase I study.
Nov 2003 - J. Hematother. Stem Cell Res.; 12(5):1525-8165 [PMID:14594508]
[Babatz J] [Röllig C] [Oelschlägel U] [Zhao S] [Ehninger G] [Schmitz M] [Bornhäuser M]